Mainstream Capital Management LLC Takes $55,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mainstream Capital Management LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 600 shares of the biopharmaceutical company’s stock, valued at approximately $55,000.

A number of other institutional investors have also recently added to or reduced their stakes in GILD. Avior Wealth Management LLC grew its holdings in Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock worth $782,000 after acquiring an additional 108 shares in the last quarter. Southland Equity Partners LLC boosted its stake in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after acquiring an additional 110 shares during the period. Concord Asset Management LLC VA grew its holdings in shares of Gilead Sciences by 3.8% during the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 111 shares during the last quarter. Berkshire Bank raised its position in shares of Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 111 shares during the period. Finally, TFB Advisors LLC boosted its position in Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after purchasing an additional 116 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Bank of America reaffirmed a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Wells Fargo & Company raised their target price on Gilead Sciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Finally, Piper Sandler lifted their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Price Performance

NASDAQ GILD opened at $115.99 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $117.16. The stock’s 50-day moving average is $97.87 and its two-hundred day moving average is $90.45. The firm has a market cap of $144.55 billion, a P/E ratio of 313.49, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.72%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at $17,597,559.49. This represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 293,356 shares of company stock worth $29,166,240. 0.16% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.